$TSHA
Taysha Gene Therapies, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023042089 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $4.746M $2.400M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.590M $5.988M
YoY Change -1.07% -39.31%
% of Gross Profit
Research & Development $11.79M $19.79M
YoY Change -28.06% -14.39%
% of Gross Profit
Depreciation & Amortization $300.0K $400.0K
YoY Change 0.0% 33.33%
% of Gross Profit
Operating Expenses $21.00M $25.78M
YoY Change -16.26% -21.85%
Operating Profit -$16.25M -$23.38M
YoY Change -35.19% -29.11%
Interest Expense $1.471M $1.440M
YoY Change 18.53% 57.89%
% of Operating Profit
Other Income/Expense, Net -$100.8M -$1.214M
YoY Change 8078.18% 36.71%
Pretax Income -$117.1M -$24.60M
YoY Change 345.09% -27.38%
Income Tax
% Of Pretax Income
Net Earnings -$117.1M -$24.60M
YoY Change 345.08% -27.38%
Net Earnings / Revenue -2467.07% -1024.92%
Basic Earnings Per Share -$0.93 -$0.38
Diluted Earnings Per Share -$0.93 -$0.38
COMMON SHARES
Basic Shares Outstanding 64.47M 64.18M
Diluted Shares Outstanding 125.7M 64.24M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $164.3M $45.08M
YoY Change 378.92% -31.94%
Cash & Equivalents $164.3M $45.08M
Short-Term Investments
Other Short-Term Assets $404.0K $510.0K
YoY Change 6.32% -24.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $171.8M $54.12M
YoY Change 299.53% -29.57%
LONG-TERM ASSETS
Property, Plant & Equipment $11.17M $14.14M
YoY Change -82.54% -76.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $304.0K $304.0K
YoY Change -75.58% -74.79%
Total Long-Term Assets $23.96M $27.43M
YoY Change -65.0% -58.12%
TOTAL ASSETS
Total Short-Term Assets $171.8M $54.12M
Total Long-Term Assets $23.96M $27.43M
Total Assets $195.8M $81.54M
YoY Change 75.63% -42.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.520M $10.77M
YoY Change -50.69% -55.08%
Accrued Expenses $12.60M $18.61M
YoY Change -29.56% -1.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $337.0K
YoY Change
Total Short-Term Liabilities $180.5M $50.64M
YoY Change 444.53% 17.9%
LONG-TERM LIABILITIES
Long-Term Debt $38.55M $38.35M
YoY Change 2.05% 2.06%
Other Long-Term Liabilities $3.832M $3.922M
YoY Change -2.59% 12.7%
Total Long-Term Liabilities $42.38M $42.28M
YoY Change 1.61% 2.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $180.5M $50.64M
Total Long-Term Liabilities $42.38M $42.28M
Total Liabilities $244.9M $118.7M
YoY Change 144.05% 8.24%
SHAREHOLDERS EQUITY
Retained Earnings -$560.7M -$443.7M
YoY Change 62.08% 38.83%
Common Stock $2.000K $1.000K
YoY Change 100.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$49.11M -$37.11M
YoY Change
Total Liabilities & Shareholders Equity $195.8M $81.54M
YoY Change 75.63% -42.71%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$117.1M -$24.60M
YoY Change 345.08% -27.38%
Depreciation, Depletion And Amortization $300.0K $400.0K
YoY Change 0.0% 33.33%
Cash From Operating Activities -$17.95M -$18.77M
YoY Change -37.36% -43.49%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$48.00K
YoY Change -100.0% -99.39%
Acquisitions
YoY Change
Other Investing Activities -$3.490M $0.00
YoY Change 249.0% -100.0%
Cash From Investing Activities -$3.490M $48.00K
YoY Change 15.56% -100.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 140.6M 377.0K
YoY Change -54607.75% -96.55%
NET CHANGE
Cash From Operating Activities -17.95M -18.77M
Cash From Investing Activities -3.490M 48.00K
Cash From Financing Activities 140.6M 377.0K
Net Change In Cash 119.2M -18.34M
YoY Change -473.25% -39.65%
FREE CASH FLOW
Cash From Operating Activities -$17.95M -$18.77M
Capital Expenditures $0.00 -$48.00K
Free Cash Flow -$17.95M -$18.72M
YoY Change -32.61% -26.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001806310
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
CY2022Q2 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2023Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2023Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q2 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#Liabilities
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39536
dei Entity Registrant Name
EntityRegistrantName
Taysha Gene Therapies, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3199512
dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Pegasus Park Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 1430
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
dei City Area Code
CityAreaCode
214
dei Local Phone Number
LocalPhoneNumber
612-0000
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
TSHA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64465037
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45083000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87880000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9032000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
54115000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96417000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2637000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14139000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10348000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10943000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
304000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1316000
CY2023Q2 us-gaap Assets
Assets
81543000
CY2022Q4 us-gaap Assets
Assets
126276000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10766000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10946000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
19632000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20243000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33557000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
50641000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62790000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6212000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
38354000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37967000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19528000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20440000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3922000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4130000
CY2023Q2 us-gaap Liabilities
Liabilities
118657000
CY2022Q4 us-gaap Liabilities
Liabilities
125327000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64432637
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64432637
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63207507
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63207507
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
406546000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
402389000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-443661000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401441000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37114000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81543000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126276000
CY2023Q2 us-gaap Revenues
Revenues
2395000
us-gaap Revenues
Revenues
7101000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19791000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23506000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32305000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61688000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5988000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9867000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14739000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21336000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
25779000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
33373000
us-gaap Operating Expenses
OperatingExpenses
47044000
us-gaap Operating Expenses
OperatingExpenses
83024000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23384000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33373000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39943000
us-gaap Operating Income Loss
OperatingIncomeLoss
-83024000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
223000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
27000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
542000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
41000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1440000
CY2022Q2 us-gaap Interest Expense
InterestExpense
743000
us-gaap Interest Expense
InterestExpense
2814000
us-gaap Interest Expense
InterestExpense
1415000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1214000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-719000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2277000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1385000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24598000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34092000
us-gaap Net Income Loss
NetIncomeLoss
-42220000
us-gaap Net Income Loss
NetIncomeLoss
-84409000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64244531
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64244531
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40142403
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40142403
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63755435
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63755435
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39163996
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39163996
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-14948000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2222000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24598000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37114000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
50741000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4249000
CY2022Q2 tsha Payment Of Sales Commissions And Other Offering Costs
PaymentOfSalesCommissionsAndOtherOfferingCosts
392000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11609000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34092000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
32507000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3897000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
us-gaap Net Income Loss
NetIncomeLoss
-42220000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37114000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95383000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9702000
tsha Payment Of Sales Commissions And Other Offering Costs
PaymentOfSalesCommissionsAndOtherOfferingCosts
392000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11609000
us-gaap Net Income Loss
NetIncomeLoss
-84409000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
32507000
us-gaap Profit Loss
ProfitLoss
-42220000
us-gaap Profit Loss
ProfitLoss
-84409000
us-gaap Depreciation
Depreciation
674000
us-gaap Depreciation
Depreciation
533000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
3500000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1250000
us-gaap Share Based Compensation
ShareBasedCompensation
3897000
us-gaap Share Based Compensation
ShareBasedCompensation
9470000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
603000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
646000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-387000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-387000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-509000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-80000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2123000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6212000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-1324000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-8461000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7101000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38952000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74292000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3250000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3852000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16290000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3852000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19540000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11640000
tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
387000
tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
227000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
50000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
321000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-156000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-766000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10968000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42797000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-82864000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90517000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47720000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68876000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45083000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66239000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
2637000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47720000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68876000
us-gaap Interest Paid Net
InterestPaidNet
2399000
us-gaap Interest Paid Net
InterestPaidNet
935000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
2722000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
18925000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
tsha Issuance Of Warrants In Connection With Private Placement
IssuanceOfWarrantsInConnectionWithPrivatePlacement
252000
tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
3500000
tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
1000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-443700000
us-gaap Depreciation
Depreciation
500000
CY2023Q2 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
7016000
CY2022Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8190000
CY2023Q2 tsha Accrued License Fees Current
AccruedLicenseFeesCurrent
3500000
CY2023Q2 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
2159000
CY2022Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1473000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the initial public offering ("IPO") (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the measurement of impairment of long-lived assets, and the allocation of consideration received in connection with the Astellas Transactions. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 tsha Derecognized Build To Suit Lease Asset Presented In Property Plant Equipment
DerecognizedBuildToSuitLeaseAssetPresentedInPropertyPlantEquipment
26300000
CY2023Q2 tsha Derecognized Build To Suit Lease Liability
DerecognizedBuildToSuitLeaseLiability
26500000
CY2023Q2 tsha Deferred Rent Liabiilities And Tenant Improvement Allowances
DeferredRentLiabiilitiesAndTenantImprovementAllowances
700000
CY2023Q2 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61688000
us-gaap Interest Expense
InterestExpense
1415000
us-gaap Net Income Loss
NetIncomeLoss
-84409000
us-gaap Depreciation
Depreciation
533000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
646000
tsha Increase Decrease In Accrued Expense And Other Current Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherCurrentLiabilities
-8461000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-766000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
18925000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23506000
CY2022Q2 us-gaap Interest Expense
InterestExpense
743000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34092000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2049000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2519000
CY2023Q2 tsha Accrued Severance
AccruedSeverance
1754000
CY2022Q4 tsha Accrued Severance
AccruedSeverance
1463000
CY2023Q2 tsha Lease Liability Current
LeaseLiabilityCurrent
1638000
CY2022Q4 tsha Lease Liability Current
LeaseLiabilityCurrent
1521000
CY2023Q2 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
4470000
CY2022Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
4840000
CY2023Q2 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2972000
CY2022Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2119000
CY2023Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
724000
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
724000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
333000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
388000
CY2023Q2 tsha Prepaid Bonus
PrepaidBonus
23000
CY2022Q4 tsha Prepaid Bonus
PrepaidBonus
18000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
510000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
448000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9032000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16450000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16605000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2311000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1642000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14139000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2022Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
36400000
CY2022Q4 tsha Construction In Progress And Finance Lease Right Of Use Asset
ConstructionInProgressAndFinanceLeaseRightOfUseAsset
26300000
CY2023Q2 us-gaap Depreciation
Depreciation
400000
CY2022Q2 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
700000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
580000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
390000
CY2023Q2 tsha Warrant Liability Current
WarrantLiabilityCurrent
252000
CY2022Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
2081000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
684000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
650000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
19632000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
708000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
535000
us-gaap Operating Lease Cost
OperatingLeaseCost
1360000
us-gaap Operating Lease Cost
OperatingLeaseCost
1108000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
243000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
194000
us-gaap Variable Lease Cost
VariableLeaseCost
486000
us-gaap Variable Lease Cost
VariableLeaseCost
387000
CY2023Q2 us-gaap Lease Cost
LeaseCost
951000
CY2022Q2 us-gaap Lease Cost
LeaseCost
729000
us-gaap Lease Cost
LeaseCost
1846000
us-gaap Lease Cost
LeaseCost
1495000
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M17D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M17D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y25D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y5M12D
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1052
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1051
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0775
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0772
us-gaap Operating Lease Payments
OperatingLeasePayments
1631000
us-gaap Operating Lease Payments
OperatingLeasePayments
726000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1425000
CY2023Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
227000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2918000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
454000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3021000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
454000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2485000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
399000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2577000
CY2023Q2 tsha Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
19721000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
32147000
CY2023Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1534000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11318000
CY2023Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
273000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
20829000
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1261000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1301000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
337000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19528000
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
924000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
20829000
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1261000
CY2022Q4 tsha Probability Of An Option Exercise
ProbabilityOfAnOptionExercise
0.50
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3100000
CY2023Q2 us-gaap Revenues
Revenues
2400000
us-gaap Revenues
Revenues
7100000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20200000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6200000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000.0
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2021Q3 tsha Percentage Of Annual Default Interest Rate
PercentageOfAnnualDefaultInterestRate
0.05
CY2023Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1400000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2700000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6667000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
13333000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1646000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
38354000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1067682
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
3160375
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
-5191357
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
-3375324
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2412024
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2222000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4141000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3897000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9470000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24598000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34092000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42220000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-84409000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64244531
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64244531
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40142403
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40142403
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63755435
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63755435
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39163996
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39163996
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9269449
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6703054
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000

Files In Submission

Name View Source Status
0000950170-23-042089-index-headers.html Edgar Link pending
0000950170-23-042089-index.html Edgar Link pending
0000950170-23-042089.txt Edgar Link pending
0000950170-23-042089-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img38648535_0.jpg Edgar Link pending
img38648535_1.jpg Edgar Link pending
img38648535_10.jpg Edgar Link pending
img38648535_11.jpg Edgar Link pending
img38648535_12.jpg Edgar Link pending
img38648535_13.jpg Edgar Link pending
img38648535_14.jpg Edgar Link pending
img38648535_15.jpg Edgar Link pending
img38648535_16.jpg Edgar Link pending
img38648535_17.jpg Edgar Link pending
img38648535_18.jpg Edgar Link pending
img38648535_19.jpg Edgar Link pending
img38648535_2.jpg Edgar Link pending
img38648535_20.jpg Edgar Link pending
img38648535_21.jpg Edgar Link pending
img38648535_22.jpg Edgar Link pending
img38648535_23.jpg Edgar Link pending
img38648535_24.jpg Edgar Link pending
img38648535_25.jpg Edgar Link pending
img38648535_26.gif Edgar Link pending
img38648535_27.jpg Edgar Link pending
img38648535_28.jpg Edgar Link pending
img38648535_3.jpg Edgar Link pending
img38648535_4.jpg Edgar Link pending
img38648535_5.jpg Edgar Link pending
img38648535_6.jpg Edgar Link pending
img38648535_7.jpg Edgar Link pending
img38648535_8.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img38648535_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-20230630.htm Edgar Link pending
tsha-20230630.xsd Edgar Link pending
tsha-ex10_1.htm Edgar Link pending
tsha-ex31_1.htm Edgar Link pending
tsha-ex31_2.htm Edgar Link pending
tsha-ex32_1.htm Edgar Link pending
tsha-ex32_2.htm Edgar Link pending
tsha-20230630_cal.xml Edgar Link unprocessable
tsha-20230630_def.xml Edgar Link unprocessable
tsha-20230630_lab.xml Edgar Link unprocessable
tsha-20230630_pre.xml Edgar Link unprocessable
tsha-20230630_htm.xml Edgar Link completed